Recently, Australian AI expert Paul Conyngham successfully developed an experimental treatment plan for his dog Rosie, who suffers from an incurable disease (mast cell cancer), by collaborating with multiple large models such as ChatGPT, AlphaFold, and Grok, marking an important step in the field of generative AI assisting complex medical decision-making.

This project started in November 2024. Following ChatGPT's recommendation, Conyngham conducted deep genomic sequencing on the lesion. Then, an AI system was used to identify specific target proteins and screen out relevant drugs that have been approved by the FDA. The key vaccine design stage was completed by the Grok model. According to the latest data, after receiving this treatment plan, the tumor has shrunk by about 75%. Although it has not been fully cured, the potential of AI in precision medicine has attracted high attention from industry leaders such as OpenAI President Greg Brockman and DeepMind CEO Demis Hassabis.

Cats, Dogs, Pets

However, biotechnology experts are cautious about this. Egan Peltan, a PhD in chemical biology from Stanford University, pointed out that the role of AI in this case may be partially exaggerated, and since the patient also received traditional immunotherapy at the same time, the actual contribution of the vaccine remains to be verified; meanwhile, the estimated cost of such personalized therapy is expected to be between $20,000 and $50,000.

Although researchers have warned that proving the long-term safety and effectiveness of drugs remains a huge challenge, this case demonstrates that AI is empowering non-medical professionals to handle complex biological information. With the popularity of tools like AlphaFold, AI-driven personalized medicine is accelerating from the laboratory to real-world applications. Although regulation and clinical validation remain core barriers, this interdisciplinary collaboration model indicates a fundamental transformation in future medical R&D efficiency.